Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.68 |
| ▸ | MAG | P20916 | 10/20 | 0.64 |
| ▸ | SELL | P14151 | 1/20 | 0.58 |
| ▸ | SELP | P16109 | 1/20 | 0.58 |
| ▸ | SELE | P16581 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31717356 | 1.00 | SIGLEC7 (0.68) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL31700333 | 1.00 | SIGLEC7 (0.68) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL31716426 | 1.00 | SIGLEC7 (0.68) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL30653356 | 1.00 | SIGLEC7 (0.68) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL31700918 | 1.00 | SIGLEC7 (0.68) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL31717039 | 0.98 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL30894716 | 0.98 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL31700317 | 0.98 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL31717064 | 0.98 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL31700356 | 0.98 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188503-A1 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2025-06-12 | — | — | US | claimed |
| WO-2025059104-A1 | METHODS AND COMPOSITIONS FOR TREATING AGE-RELATED NEURODEGENERATIVE DISEASE ASSOCIATED WITH DYSBIOSIS | INTRINSIC MEDICINE, INC. (US) | 2025-03-20 | — | — | WO | claimed |
| US-20240299430-A1 | METHODS AND COMPOSITIONS FOR TREATING LONG COVID-19 | TARGET CAPITAL 4 LLC | 2024-09-12 | — | — | US | claimed |
| US-20240216406-A1 | METHODS AND COMPOSITIONS FOR SUPPORTING HUMAN HEALTH DURING SPACE TRAVEL | INTRINSIC MEDICINE INC (US) | 2024-07-04 | — | — | US | claimed |
| US-20240041908-A1 | IMMUNOMODULATORY OLIGOSACCHARIDES FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | TARGET CAPITAL 4 LLC | 2024-02-08 | — | — | US | claimed |
| EP-4277475-A1 | METHODS AND COMPOSITIONS FOR SUPPORTING HUMAN HEALTH DURING SPACE TRAVEL | Intrinsic Medicine, Inc. (US) | 2023-11-22 | — | — | EP | claimed |
| WO-2023192161-A2 | METHODS AND COMPOSITIONS FOR ATTENUATING IMMUNE RESPONSE ASSOCIATED WITH RNA THERAPEUTICS | INTRINSIC MEDICINE, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| US-20230270788-A1 | COMPOSITION FOR AUGMENTING STEMNESS AND USE THEREOF | GENECHEM INC. (KR) | 2023-08-31 | — | — | US | claimed |
| EP-4199932-A1 | IMMUNOMODULATORY OLIGOSACCHARIDES FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | Intrinsic Medicine, Inc. (US) | 2023-06-28 | — | — | EP | claimed |
| US-20230058412-A1 | Carbohydrate-Modified Particles and Particulate Formulations for Modulating an Immune Response | NORTHWESTERN UNIVERSITY | 2023-02-23 | — | — | US | claimed |
| US-20230031433-A1 | COMPOSITIONS AND METHODS FOR MANAGING INFECTIONS OF A URINARY TRACT | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2023-02-02 | — | — | US | claimed |
| EP-4076473-A1 | COMPOSITIONS AND METHODS FOR MANAGING INFECTIONS OF A URINARY TRACT | METAGENICS, INC. (US) | 2022-10-26 | — | — | EP | claimed |
| WO-2022221349-A2 | METHODS AND COMPOSITIONS FOR TREATING LONG COVID-19 | INTRINSIC MEDICINE, INC. (US) | 2022-10-20 | — | — | WO | claimed |
| EP-4043550-A2 | COMPOSITION FOR AUGMENTING STEMNESS AND USE THEREOF | Genechem Inc. (KR) | 2022-08-17 | — | — | EP | claimed |
| WO-2022155126-A1 | METHODS AND COMPOSITIONS FOR SUPPORTING HUMAN HEALTH DURING SPACE TRAVEL | INTRINSIC MEDICINE, INC. (US) | 2022-07-21 | — | — | WO | claimed |
| US-20220218727-A1 | METHODS AND COMPOSITIONS OF SUPPORTING HUMAN HEALTH DURING SPACE TRAVEL | INTRINSIC MEDICINE, INC. | 2022-07-14 | — | — | US | claimed |
| WO-2022046501-A1 | IMMUNOMODULATORY OLIGOSACCHARIDES FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | INTRINSIC MEDICINE, INC. (US) | 2022-03-03 | — | — | WO | claimed |
| US-20260139285-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | INBIOSE N V (BE) | 2026-05-21 | — | — | US | disclosed |
| US-20220099666-A1 | MULTIVALENT GLYCAN MICROARRAY PLATFORM | Z BIOTECH, LLC (US) | 2022-03-31 | — | — | US | disclosed |
| WO-2022046501-A1 | IMMUNOMODULATORY OLIGOSACCHARIDES FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | INTRINSIC MEDICINE, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299430-A1 | METHODS AND COMPOSITIONS FOR TREATING LONG COVID-19 | FUT6, FUT5, ACE2 | SIGLEC7 42/4885MAG 281/4885SELL 473/4885 |
| US-20240041908-A1 | IMMUNOMODULATORY OLIGOSACCHARIDES FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | SIGLEC7, LGALS4, LGALS8 | SIGLEC7 1/4885MAG 12/4885SELL 866/4885 |
| US-20240216406-A1 | METHODS AND COMPOSITIONS FOR SUPPORTING HUMAN HEALTH DURING SPACE TRAVEL | FUT6, FUT5, FUCA2 | SIGLEC7 195/4885MAG 489/4885SELL 709/4885 |
| US-20260139285-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | GALNT3, NANS, ENGASE | SIGLEC7 512/4885MAG 1618/4885SELL 599/4885 |
| US-20220218727-A1 | METHODS AND COMPOSITIONS OF SUPPORTING HUMAN HEALTH DURING SPACE TRAVEL | FUT6, FUT5, FUCA2 | SIGLEC7 195/4885MAG 525/4885SELL 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.